• Clinuvel outlined a profitable track record through Dec. 31, 2025, with zero debt, cash reserves of US$155 million, and a 3+ year cash runway.
• Pipeline focus remains SCENESSE (afamelanotide 16 mg), marketed for adult EPP across Europe, Switzerland, the US, Iceland, and Canada under review.
• Regulatory filing for SCENESSE in adolescent EPP targeted for H2 2026; topline results for the CUV105 vitiligo study also slated for H2 2026.
• NEURACTHEL instant is positioned for infantile spasms and multiple sclerosis, with a first European filing expected in mid 2026.
• VLRX-L controlled-release peptide platform flagged for preclinical results in H2 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clinuvel Pharmaceuticals Limited published the original content used to generate this news brief on June 02, 2026, and is solely responsible for the information contained therein.